News stories about Versartis (NASDAQ:VSAR) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Versartis earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.1913434823272 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several research firms have recently weighed in on VSAR. Cantor Fitzgerald set a $14.00 price objective on shares of Versartis and gave the stock a “buy” rating in a research note on Friday, October 27th. Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research note on Sunday, January 21st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $5.63.

Shares of Versartis (VSAR) traded up $0.10 during trading hours on Tuesday, hitting $1.80. 333,800 shares of the company’s stock were exchanged, compared to its average volume of 615,956. Versartis has a 1 year low of $1.60 and a 1 year high of $24.00. The firm has a market cap of $60.88, a price-to-earnings ratio of -0.46 and a beta of 2.11. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.52 and a current ratio of 1.52.

In other Versartis news, insider Jay Shepard sold 14,446 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $1.80, for a total transaction of $26,002.80. Following the transaction, the insider now owns 602,298 shares in the company, valued at approximately $1,084,136.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju bought 513,872 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were acquired at an average price of $2.21 per share, for a total transaction of $1,135,657.12. Following the transaction, the director now owns 14,955 shares in the company, valued at $33,050.55. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 21,400 shares of company stock worth $38,520. Company insiders own 10.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/versartis-vsar-earning-somewhat-favorable-press-coverage-report-finds.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.